Abstract
BackgroundBetter objective measures are needed to evaluate the responses to biologics in rheumatoid arthritis (RA) patients because such responses are not predictable and useful indicators remain unclear. Furthermore, to predict...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have